-
1
-
-
0034685403
-
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
-
ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283:1967–1975.
-
(2000)
JAMA
, vol.283
, pp. 1967-1975
-
-
-
2
-
-
0026786643
-
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial
-
Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669–677.
-
(1992)
N Engl J Med
, vol.327
, pp. 669-677
-
-
Pfeffer, M.A.1
Braunwald, E.2
Moyé, L.A.3
Basta, L.4
Brown, E.J.5
Cuddy, T.E.6
Davis, B.R.7
Geltman, E.M.8
Goldman, S.9
Flaker, G.C.10
Klein, M.11
Lamas, G.A.12
Packer, M.13
Rouleau, J.14
Rouleau, J.L.15
Rutherford, J.16
Wertheimer, J.H.17
Hawkins, C.M.18
-
3
-
-
0035810547
-
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial
-
Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385–1390.
-
(2001)
Lancet
, vol.357
, pp. 1385-1390
-
-
Dargie, H.J.1
-
4
-
-
0037417252
-
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
-
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–1321.
-
(2003)
N Engl J Med
, vol.348
, pp. 1309-1321
-
-
Pitt, B.1
Remme, W.2
Zannad, F.3
Neaton, J.4
Martinez, F.5
Roniker, B.6
Bittman, R.7
Hurley, S.8
Kleiman, J.9
Gatlin, M.10
-
5
-
-
0023266532
-
Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
-
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429–1435.
-
(1987)
N Engl J Med
, vol.316
, pp. 1429-1435
-
-
-
6
-
-
0035978763
-
Effect of carvedilol on survival in severe chronic heart failure
-
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658.
-
(2001)
N Engl J Med
, vol.344
, pp. 1651-1658
-
-
Packer, M.1
Coats, A.J.2
Fowler, M.B.3
Katus, H.A.4
Krum, H.5
Mohacsi, P.6
Rouleau, J.L.7
Tendera, M.8
Castaigne, A.9
Roecker, E.B.10
Schultz, M.K.11
DeMets, D.L.12
-
7
-
-
0033517302
-
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
-
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–717.
-
(1999)
N Engl J Med
, vol.341
, pp. 709-717
-
-
Pitt, B.1
Zannad, F.2
Remme, W.J.3
Cody, R.4
Castaigne, A.5
Perez, A.6
Palensky, J.7
Wittes, J.8
-
8
-
-
0037149716
-
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction
-
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–883.
-
(2002)
N Engl J Med
, vol.346
, pp. 877-883
-
-
Moss, A.J.1
Zareba, W.2
Hall, W.J.3
Klein, H.4
Wilber, D.J.5
Cannom, D.S.6
Daubert, J.P.7
Higgins, S.L.8
Brown, M.W.9
Andrews, M.L.10
-
9
-
-
19944429413
-
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure
-
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–237.
-
(2005)
N Engl J Med
, vol.352
, pp. 225-237
-
-
Bardy, G.H.1
Lee, K.L.2
Mark, D.B.3
Poole, J.E.4
Packer, D.L.5
Boineau, R.6
Domanski, M.7
Troutman, C.8
Anderson, J.9
Johnson, G.10
McNulty, S.E.11
Clapp-Channing, N.12
Davidson-Ray, L.D.13
Fraulo, E.S.14
Fishbein, D.P.15
Luceri, R.M.16
Ip, J.H.17
-
10
-
-
84937584846
-
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials
-
Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioli R, Tognoni G, Athyros VG, Ray KK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J 2015;36:1536–1546.
-
(2015)
Eur Heart J
, vol.36
, pp. 1536-1546
-
-
Preiss, D.1
Campbell, R.T.2
Murray, H.M.3
Ford, I.4
Packard, C.J.5
Sattar, N.6
Rahimi, K.7
Colhoun, H.M.8
Waters, D.D.9
LaRosa, J.C.10
Amarenco, P.11
Pedersen, T.R.12
Tikkanen, M.J.13
Koren, M.J.14
Poulter, N.R.15
Sever, P.S.16
Ridker, P.M.17
MacFadyen, J.G.18
Solomon, S.D.19
Davis, B.R.20
Simpson, L.M.21
Nakamura, H.22
Mizuno, K.23
Marfisi, R.M.24
Marchioli, R.25
Tognoni, G.26
Athyros, V.G.27
Ray, K.K.28
Gotto, A.M.29
Clearfield, M.B.30
Downs, J.R.31
McMurray, J.J.32
more..
-
11
-
-
33846879844
-
Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study
-
Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, Wenger NK. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007;115:576–583.
-
(2007)
Circulation
, vol.115
, pp. 576-583
-
-
Khush, K.K.1
Waters, D.D.2
Bittner, V.3
Deedwania, P.C.4
Kastelein, J.J.5
Lewis, S.J.6
Wenger, N.K.7
-
12
-
-
36549030340
-
Rosuvastatin in older patients with systolic heart failure
-
Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248–2261.
-
(2007)
N Engl J Med
, vol.357
, pp. 2248-2261
-
-
Kjekshus, J.1
Apetrei, E.2
Barrios, V.3
Böhm, M.4
Cleland, J.G.5
Cornel, J.H.6
Dunselman, P.7
Fonseca, C.8
Goudev, A.9
Grande, P.10
Gullestad, L.11
Hjalmarson, A.12
Hradec, J.13
Jánosi, A.14
Kamenský, G.15
Komajda, M.16
Korewicki, J.17
Kuusi, T.18
Mach, F.19
Mareev, V.20
McMurray, J.J.21
Ranjith, N.22
Schaufelberger, M.23
Vanhaecke, J.24
van Veldhuisen, D.J.25
Waagstein, F.26
Wedel, H.27
Wikstrand, J.28
more..
-
13
-
-
53049095795
-
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
-
Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231–1239.
-
(2008)
Lancet
, vol.372
, pp. 1231-1239
-
-
Tavazzi, L.1
Maggioni, A.P.2
Marchioli, R.3
Barlera, S.4
Franzosi, M.G.5
Latini, R.6
Lucci, D.7
Nicolosi, G.L.8
Porcu, M.9
Tognoni, G.10
-
14
-
-
84926141742
-
Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF
-
Feinstein MJ, Jhund P, Kang J, Ning H, Maggioni A, Wikstrand J, Kjekshus J, Tavazzi L, McMurray J, Lloyd-Jones DM. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. Eur J Heart Fail 2015;17:434–441.
-
(2015)
Eur J Heart Fail
, vol.17
, pp. 434-441
-
-
Feinstein, M.J.1
Jhund, P.2
Kang, J.3
Ning, H.4
Maggioni, A.5
Wikstrand, J.6
Kjekshus, J.7
Tavazzi, L.8
McMurray, J.9
Lloyd-Jones, D.M.10
-
15
-
-
85021770915
-
Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction
-
Obokata M, Reddy YN, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017;136:6–19.
-
(2017)
Circulation
, vol.136
, pp. 6-19
-
-
Obokata, M.1
Reddy, Y.N.2
Pislaru, S.V.3
Melenovsky, V.4
Borlaug, B.A.5
-
16
-
-
84990221063
-
The HFpEF obesity phenotype: the elephant in the room
-
Kitzman DW, Shah SJ. The HFpEF obesity phenotype: the elephant in the room. J Am Coll Cardiol 2016;68:200–203.
-
(2016)
J Am Coll Cardiol
, vol.68
, pp. 200-203
-
-
Kitzman, D.W.1
Shah, S.J.2
-
17
-
-
85025481432
-
Targeting obesity and diabetes to treat heart failure with preserved ejection fraction
-
Altara R, Giordano M, Nordén ES, Cataliotti A, Kurdi M, Bajestani SN, Booz GW. Targeting obesity and diabetes to treat heart failure with preserved ejection fraction. Front Endocrinol (Lausanne) 2017;8:160.
-
(2017)
Front Endocrinol (Lausanne)
, vol.8
, pp. 160
-
-
Altara, R.1
Giordano, M.2
Nordén, E.S.3
Cataliotti, A.4
Kurdi, M.5
Bajestani, S.N.6
Booz, G.W.7
-
18
-
-
85045013446
-
Association of hemoglobin A1c variability and the incidence of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and arterial hypertension
-
Aug 15., [Epub ahead of print]
-
Gu J, Fan YQ, Zhang JF, Wang CQ. Association of hemoglobin A1c variability and the incidence of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and arterial hypertension. Hellenic J Cardiol 2017 Aug 15. https://doi.org/10.1016/j.hjc.2017.08.001. [Epub ahead of print]
-
(2017)
Hellenic J Cardiol
-
-
Gu, J.1
Fan, Y.Q.2
Zhang, J.F.3
Wang, C.Q.4
-
19
-
-
84954323250
-
The association and interaction analysis of hypertension and diabetes mellitus on diastolic heart failure in a high-risk population
-
Meng XY, Zhou Y, Zhang J, Tang ZH. The association and interaction analysis of hypertension and diabetes mellitus on diastolic heart failure in a high-risk population. Int J Clin Exp Med 2015;8:21311–21318.
-
(2015)
Int J Clin Exp Med
, vol.8
, pp. 21311-21318
-
-
Meng, X.Y.1
Zhou, Y.2
Zhang, J.3
Tang, Z.H.4
-
20
-
-
84947429178
-
Increased epicardial adipose tissue thickness in type 2 diabetes mellitus and obesity
-
Song DK, Hong YS, Lee H, Oh JY, Sung YA, Kim Y. Increased epicardial adipose tissue thickness in type 2 diabetes mellitus and obesity. Diabetes Metab J 2015;39:405–413.
-
(2015)
Diabetes Metab J
, vol.39
, pp. 405-413
-
-
Song, D.K.1
Hong, Y.S.2
Lee, H.3
Oh, J.Y.4
Sung, Y.A.5
Kim, Y.6
-
21
-
-
84926683179
-
Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines
-
Venteclef N, Guglielmi V, Balse E, Gaborit B, Cotillard A, Atassi F, Amour J, Leprince P, Dutour A, Clément K, Hatem SN. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J 2015;36:795–805.
-
(2015)
Eur Heart J
, vol.36
, pp. 795-805
-
-
Venteclef, N.1
Guglielmi, V.2
Balse, E.3
Gaborit, B.4
Cotillard, A.5
Atassi, F.6
Amour, J.7
Leprince, P.8
Dutour, A.9
Clément, K.10
Hatem, S.N.11
-
22
-
-
48349146146
-
The double role of epicardial adipose tissue as pro- and anti-inflammatory organ
-
Iacobellis G, Barbaro G. The double role of epicardial adipose tissue as pro- and anti-inflammatory organ. Horm Metab Res 2008;40:442–445.
-
(2008)
Horm Metab Res
, vol.40
, pp. 442-445
-
-
Iacobellis, G.1
Barbaro, G.2
-
23
-
-
84929966037
-
Local and systemic effects of the multifaceted epicardial adipose tissue depot
-
Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol 2015;11:363–371.
-
(2015)
Nat Rev Endocrinol
, vol.11
, pp. 363-371
-
-
Iacobellis, G.1
-
24
-
-
84944355526
-
Effects of atorvastatin (80 mg) therapy on quantity of epicardial adipose tissue in patients undergoing pulmonary vein isolation for atrial fibrillation
-
Soucek F, Covassin N, Singh P, Ruzek L, Kara T, Suleiman M, Lerman A, Koestler C, Friedman PA, Lopez-Jimenez F, Somers VK. Effects of atorvastatin (80 mg) therapy on quantity of epicardial adipose tissue in patients undergoing pulmonary vein isolation for atrial fibrillation. Am J Cardiol 2015;116:1443–1446.
-
(2015)
Am J Cardiol
, vol.116
, pp. 1443-1446
-
-
Soucek, F.1
Covassin, N.2
Singh, P.3
Ruzek, L.4
Kara, T.5
Suleiman, M.6
Lerman, A.7
Koestler, C.8
Friedman, P.A.9
Lopez-Jimenez, F.10
Somers, V.K.11
-
25
-
-
85019168137
-
Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome
-
Yamada Y, Takeuchi S, Yoneda M, Ito S, Sano Y, Nagasawa K, Matsuura N, Uchinaka A, Murohara T, Nagata K. Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome. Int J Cardiol 2017;240:332–338.
-
(2017)
Int J Cardiol
, vol.240
, pp. 332-338
-
-
Yamada, Y.1
Takeuchi, S.2
Yoneda, M.3
Ito, S.4
Sano, Y.5
Nagasawa, K.6
Matsuura, N.7
Uchinaka, A.8
Murohara, T.9
Nagata, K.10
-
26
-
-
84875458263
-
Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning)
-
Alexopoulos N, Melek BH, Arepalli CD, Hartlage GR, Chen Z, Kim S, Stillman AE, Raggi P. Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning). J Am Coll Cardiol 2013;61:1956–1961.
-
(2013)
J Am Coll Cardiol
, vol.61
, pp. 1956-1961
-
-
Alexopoulos, N.1
Melek, B.H.2
Arepalli, C.D.3
Hartlage, G.R.4
Chen, Z.5
Kim, S.6
Stillman, A.E.7
Raggi, P.8
-
27
-
-
42149193750
-
Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages
-
Abe M, Matsuda M, Kobayashi H, Miyata Y, Nakayama Y, Komuro R, Fukuhara A, Shimomura I. Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages. Arterioscler Thromb Vasc Biol 2008;28:871–877.
-
(2008)
Arterioscler Thromb Vasc Biol
, vol.28
, pp. 871-877
-
-
Abe, M.1
Matsuda, M.2
Kobayashi, H.3
Miyata, Y.4
Nakayama, Y.5
Komuro, R.6
Fukuhara, A.7
Shimomura, I.8
-
28
-
-
38749102425
-
Effects of atorvastatin on the different phases of atherogenesis
-
Rubba P. Effects of atorvastatin on the different phases of atherogenesis. Drugs 2007;67 Suppl 1:17–27.
-
(2007)
Drugs
, vol.67
, pp. 17-27
-
-
Rubba, P.1
-
29
-
-
84901236373
-
Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors
-
Nie P, Li D, Hu L, Jin S, Yu Y, Cai Z, Shao Q, Shen J, Yi J, Xiao H, Shen L, He B. Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors. PLoS One 2014;9:e97009.
-
(2014)
PLoS One
, vol.9
-
-
Nie, P.1
Li, D.2
Hu, L.3
Jin, S.4
Yu, Y.5
Cai, Z.6
Shao, Q.7
Shen, J.8
Yi, J.9
Xiao, H.10
Shen, L.11
He, B.12
-
30
-
-
78650840067
-
Perivascular adipose tissue as a cause of atherosclerosis
-
Verhagen SN, Visseren FL. Perivascular adipose tissue as a cause of atherosclerosis. Atherosclerosis 2011;214:3–10.
-
(2011)
Atherosclerosis
, vol.214
, pp. 3-10
-
-
Verhagen, S.N.1
Visseren, F.L.2
-
31
-
-
79151483849
-
Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels
-
Bot I, Jukema JW, Lankhuizen IM, van Berkel TJ, Biessen EA. Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels. Atherosclerosis 2011;214:295–300.
-
(2011)
Atherosclerosis
, vol.214
, pp. 295-300
-
-
Bot, I.1
Jukema, J.W.2
Lankhuizen, I.M.3
van Berkel, T.J.4
Biessen, E.A.5
-
32
-
-
77958487910
-
Association of epicardial adipose tissue with coronary atherosclerosis is region-specific and independent of conventional risk factors and intra-abdominal adiposity
-
Wang TD, Lee WJ, Shih FY, Huang CH, Chen WJ, Lee YT, Shih TT, Chen MF. Association of epicardial adipose tissue with coronary atherosclerosis is region-specific and independent of conventional risk factors and intra-abdominal adiposity. Atherosclerosis 2010;213:279–287.
-
(2010)
Atherosclerosis
, vol.213
, pp. 279-287
-
-
Wang, T.D.1
Lee, W.J.2
Shih, F.Y.3
Huang, C.H.4
Chen, W.J.5
Lee, Y.T.6
Shih, T.T.7
Chen, M.F.8
-
33
-
-
84880920017
-
Relationship between myocardial bridges and reduced coronary atherosclerosis in patients with angina pectoris
-
Verhagen SN, Rutten A, Meijs MF, Isgum I, Cramer MJ, van der Graaf Y, Visseren FL. Relationship between myocardial bridges and reduced coronary atherosclerosis in patients with angina pectoris. Int J Cardiol 2013;167:883–888.
-
(2013)
Int J Cardiol
, vol.167
, pp. 883-888
-
-
Verhagen, S.N.1
Rutten, A.2
Meijs, M.F.3
Isgum, I.4
Cramer, M.J.5
van der Graaf, Y.6
Visseren, F.L.7
-
34
-
-
77954312890
-
Association of pericoronary fat volume with atherosclerotic plaque burden in the underlying coronary artery: a segment analysis
-
Mahabadi AA, Reinsch N, Lehmann N, Altenbernd J, Kälsch H, Seibel RM, Erbel R, Möhlenkamp S. Association of pericoronary fat volume with atherosclerotic plaque burden in the underlying coronary artery: a segment analysis. Atherosclerosis 2010;211:195–199.
-
(2010)
Atherosclerosis
, vol.211
, pp. 195-199
-
-
Mahabadi, A.A.1
Reinsch, N.2
Lehmann, N.3
Altenbernd, J.4
Kälsch, H.5
Seibel, R.M.6
Erbel, R.7
Möhlenkamp, S.8
-
35
-
-
82355173484
-
Depot-specific overexpression of proinflammatory, redox, endothelial cell, and angiogenic genes in epicardial fat adjacent to severe stable coronary atherosclerosis
-
Sacks HS, Fain JN, Cheema P, Bahouth SW, Garrett E, Wolf RY, Wolford D, Samaha J. Depot-specific overexpression of proinflammatory, redox, endothelial cell, and angiogenic genes in epicardial fat adjacent to severe stable coronary atherosclerosis. Metab Syndr Relat Disord 2011;9:433–439.
-
(2011)
Metab Syndr Relat Disord
, vol.9
, pp. 433-439
-
-
Sacks, H.S.1
Fain, J.N.2
Cheema, P.3
Bahouth, S.W.4
Garrett, E.5
Wolf, R.Y.6
Wolford, D.7
Samaha, J.8
-
36
-
-
85026508106
-
Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease
-
Patel VB, Shah S, Verma S, Oudit GY. Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease. Heart Fail Rev 2017;22:889–902.
-
(2017)
Heart Fail Rev
, vol.22
, pp. 889-902
-
-
Patel, V.B.1
Shah, S.2
Verma, S.3
Oudit, G.Y.4
-
37
-
-
85031689841
-
ACE2/Ang 1–7 axis: a critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity
-
Patel VB, Basu R, Oudit GY. ACE2/Ang 1–7 axis: a critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity. Adipocyte 2016;5:306–311.
-
(2016)
Adipocyte
, vol.5
, pp. 306-311
-
-
Patel, V.B.1
Basu, R.2
Oudit, G.Y.3
-
38
-
-
85031406636
-
Evolutional change in epicardial fat and its correlation with myocardial diffuse fibrosis in heart failure patients
-
Wu CK, Tsai HY, Su MM, Wu YF, Hwang JJ, Lin JL, Lin LY, Chen JJ. Evolutional change in epicardial fat and its correlation with myocardial diffuse fibrosis in heart failure patients. J Clin Lipidol 2017;11:1421–1431.
-
(2017)
J Clin Lipidol
, vol.11
, pp. 1421-1431
-
-
Wu, C.K.1
Tsai, H.Y.2
Su, M.M.3
Wu, Y.F.4
Hwang, J.J.5
Lin, J.L.6
Lin, L.Y.7
Chen, J.J.8
-
39
-
-
84937391468
-
Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity
-
Mahajan R, Lau DH, Brooks AG, Shipp NJ, Manavis J, Wood JP, Finnie JW, Samuel CS, Royce SG, Twomey DJ, Thanigaimani S, Kalman JM, Sanders P. Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J Am Coll Cardiol 2015;66:1–11.
-
(2015)
J Am Coll Cardiol
, vol.66
, pp. 1-11
-
-
Mahajan, R.1
Lau, D.H.2
Brooks, A.G.3
Shipp, N.J.4
Manavis, J.5
Wood, J.P.6
Finnie, J.W.7
Samuel, C.S.8
Royce, S.G.9
Twomey, D.J.10
Thanigaimani, S.11
Kalman, J.M.12
Sanders, P.13
-
40
-
-
85016425356
-
Association of left atrial epicardial adipose tissue with electrogram bipolar voltage and fractionation: electrophysiologic substrates for atrial fibrillation
-
Zghaib T, Ipek EG, Zahid S, Balouch MA, Misra S, Ashikaga H, Berger RD, Marine JE, Spragg DD, Zimmerman SL, Zipunnikov V, Trayanova N, Calkins H, Nazarian S. Association of left atrial epicardial adipose tissue with electrogram bipolar voltage and fractionation: electrophysiologic substrates for atrial fibrillation. Heart Rhythm 2016;13:2333–2339.
-
(2016)
Heart Rhythm
, vol.13
, pp. 2333-2339
-
-
Zghaib, T.1
Ipek, E.G.2
Zahid, S.3
Balouch, M.A.4
Misra, S.5
Ashikaga, H.6
Berger, R.D.7
Marine, J.E.8
Spragg, D.D.9
Zimmerman, S.L.10
Zipunnikov, V.11
Trayanova, N.12
Calkins, H.13
Nazarian, S.14
-
41
-
-
85030159134
-
Relationships between periventricular epicardial adipose tissue accumulation, coronary microcirculation, and left ventricular diastolic dysfunction
-
Nakanishi K, Fukuda S, Tanaka A, Otsuka K, Taguchi H, Shimada K. Relationships between periventricular epicardial adipose tissue accumulation, coronary microcirculation, and left ventricular diastolic dysfunction. Can J Cardiol 2017;33:1489–1497.
-
(2017)
Can J Cardiol
, vol.33
, pp. 1489-1497
-
-
Nakanishi, K.1
Fukuda, S.2
Tanaka, A.3
Otsuka, K.4
Taguchi, H.5
Shimada, K.6
-
42
-
-
67650403810
-
Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives
-
Natale F, Tedesco MA, Mocerino R, de Simone V, Di Marco GM, Aronne L, Credendino M, Siniscalchi C, Calabrò P, Cotrufo M, Calabrò R. Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives. Eur J Echocardiogr 2009;10:549–555.
-
(2009)
Eur J Echocardiogr
, vol.10
, pp. 549-555
-
-
Natale, F.1
Tedesco, M.A.2
Mocerino, R.3
de Simone, V.4
Di Marco, G.M.5
Aronne, L.6
Credendino, M.7
Siniscalchi, C.8
Calabrò, P.9
Cotrufo, M.10
Calabrò, R.11
-
43
-
-
33846388449
-
Relationship of epicardial adipose tissue with atrial dimensions and diastolic function in morbidly obese subjects
-
Iacobellis G, Leonetti F, Singh N, Sharma AM. Relationship of epicardial adipose tissue with atrial dimensions and diastolic function in morbidly obese subjects. Int J Cardiol 2007;115:272–273.
-
(2007)
Int J Cardiol
, vol.115
, pp. 272-273
-
-
Iacobellis, G.1
Leonetti, F.2
Singh, N.3
Sharma, A.M.4
-
44
-
-
85017131584
-
Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients – the ALEVENT clinical trial
-
Wu CK, Yeh CF, Chiang JY, Lin TT, Wu YF, Chiang CK, Kao TW, Hung KY, Huang JW. Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients – the ALEVENT clinical trial. J Clin Lipidol 2017;11:657–666.
-
(2017)
J Clin Lipidol
, vol.11
, pp. 657-666
-
-
Wu, C.K.1
Yeh, C.F.2
Chiang, J.Y.3
Lin, T.T.4
Wu, Y.F.5
Chiang, C.K.6
Kao, T.W.7
Hung, K.Y.8
Huang, J.W.9
-
45
-
-
84861339380
-
Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals
-
Beck AL, Otto ME, D'Avila LB, Netto FM, Armendaris MK, Sposito AC. Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals. Atherosclerosis 2012;222:444–448.
-
(2012)
Atherosclerosis
, vol.222
, pp. 444-448
-
-
Beck, A.L.1
Otto, M.E.2
D'Avila, L.B.3
Netto, F.M.4
Armendaris, M.K.5
Sposito, A.C.6
-
46
-
-
84863096401
-
The effect of acute administration of statins on coronary microcirculation during the pre-revascularization period in patients with myocardial infarction
-
Paraskevaidis IA, Iliodromitis EK, Ikonomidis I, Rallidis L, Hamodraka E, Parissis J, Andoniadis A, Tzortzis S, Anastasiou-Nana M. The effect of acute administration of statins on coronary microcirculation during the pre-revascularization period in patients with myocardial infarction. Atherosclerosis 2012;223:184–189.
-
(2012)
Atherosclerosis
, vol.223
, pp. 184-189
-
-
Paraskevaidis, I.A.1
Iliodromitis, E.K.2
Ikonomidis, I.3
Rallidis, L.4
Hamodraka, E.5
Parissis, J.6
Andoniadis, A.7
Tzortzis, S.8
Anastasiou-Nana, M.9
-
47
-
-
85018753499
-
Inhibition of angiotensin II-induced cardiac fibrosis by atorvastatin in adiponectin knockout mice
-
Choi SY, Park JS, Roh MS, Kim CR, Kim MH, Serebruany V. Inhibition of angiotensin II-induced cardiac fibrosis by atorvastatin in adiponectin knockout mice. Lipids 2017;52:415–422.
-
(2017)
Lipids
, vol.52
, pp. 415-422
-
-
Choi, S.Y.1
Park, J.S.2
Roh, M.S.3
Kim, C.R.4
Kim, M.H.5
Serebruany, V.6
-
48
-
-
84903890376
-
Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats
-
Akahori H, Tsujino T, Naito Y, Matsumoto M, Sasaki N, Iwasaku T, Eguchi A, Sawada H, Hirotani S, Masuyama T. Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats. J Hypertens 2014;32:1534–1541.
-
(2014)
J Hypertens
, vol.32
, pp. 1534-1541
-
-
Akahori, H.1
Tsujino, T.2
Naito, Y.3
Matsumoto, M.4
Sasaki, N.5
Iwasaku, T.6
Eguchi, A.7
Sawada, H.8
Hirotani, S.9
Masuyama, T.10
-
49
-
-
84923471042
-
Statins beneficial for heart failure with preserved ejection fraction but not heart failure with reduced ejection fraction?
-
Ohte N, Little WC. Statins beneficial for heart failure with preserved ejection fraction but not heart failure with reduced ejection fraction? Circ J 2015;79:508–509.
-
(2015)
Circ J
, vol.79
, pp. 508-509
-
-
Ohte, N.1
Little, W.C.2
-
50
-
-
84963626029
-
The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses
-
Fukuta H, Goto T, Wakami K, Ohte N. The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses. Int J Cardiol 2016;214:301–306.
-
(2016)
Int J Cardiol
, vol.214
, pp. 301-306
-
-
Fukuta, H.1
Goto, T.2
Wakami, K.3
Ohte, N.4
-
51
-
-
22544443085
-
Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report
-
Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005;112:357–363.
-
(2005)
Circulation
, vol.112
, pp. 357-363
-
-
Fukuta, H.1
Sane, D.C.2
Brucks, S.3
Little, W.C.4
-
52
-
-
84896034713
-
Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction
-
Liu G, Zheng XX, Xu YL, Ru J, Hui RT, Huang XH. Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am J Cardiol 2014;113:1198–1204.
-
(2014)
Am J Cardiol
, vol.113
, pp. 1198-1204
-
-
Liu, G.1
Zheng, X.X.2
Xu, Y.L.3
Ru, J.4
Hui, R.T.5
Huang, X.H.6
-
53
-
-
84923439815
-
Prognostic impact of statin use in patients with heart failure and preserved ejection fraction
-
Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H; CHART-2 Investigators. Prognostic impact of statin use in patients with heart failure and preserved ejection fraction. Circ J 2015;79:574–582.
-
(2015)
Circ J
, vol.79
, pp. 574-582
-
-
Nochioka, K.1
Sakata, Y.2
Miyata, S.3
Miura, M.4
Takada, T.5
Tadaki, S.6
Ushigome, R.7
Yamauchi, T.8
Takahashi, J.9
Shimokawa, H.10
-
54
-
-
84876469500
-
Epicardial adipose tissue assessed by cardiac magnetic resonance imaging in patients with heart failure due to dilated cardiomyopathy
-
Doesch C, Streitner F, Bellm S, Suselbeck T, Haghi D, Heggemann F, Schoenberg SO, Michaely H, Borggrefe M, Papavassiliu T. Epicardial adipose tissue assessed by cardiac magnetic resonance imaging in patients with heart failure due to dilated cardiomyopathy. Obesity (Silver Spring) 2013;21:E253–261.
-
(2013)
Obesity (Silver Spring)
, vol.21
, pp. E253-261
-
-
Doesch, C.1
Streitner, F.2
Bellm, S.3
Suselbeck, T.4
Haghi, D.5
Heggemann, F.6
Schoenberg, S.O.7
Michaely, H.8
Borggrefe, M.9
Papavassiliu, T.10
-
55
-
-
77956135588
-
Epicardial adipose tissue in patients with heart failure
-
Doesch C, Haghi D, Flüchter S, Suselbeck T, Schoenberg SO, Michaely H, Borggrefe M, Papavassiliu T. Epicardial adipose tissue in patients with heart failure. J Cardiovasc Magn Reson 2010;12:40.
-
(2010)
J Cardiovasc Magn Reson
, vol.12
, pp. 40
-
-
Doesch, C.1
Haghi, D.2
Flüchter, S.3
Suselbeck, T.4
Schoenberg, S.O.5
Michaely, H.6
Borggrefe, M.7
Papavassiliu, T.8
-
56
-
-
85027585723
-
Expression of epicardial adipose tissue thermogenic genes in patients with reduced and preserved ejection fraction heart failure
-
Pérez-Belmonte LM, Moreno-Santos I, Gómez-Doblas JJ, García-Pinilla JM, Morcillo-Hidalgo L, Garrido-Sánchez L, Santiago-Fernández C, Crespo-Leiro MG, Carrasco-Chinchilla F, Sánchez-Fernández PL, de Teresa-Galván E, Jiménez-Navarro M. Expression of epicardial adipose tissue thermogenic genes in patients with reduced and preserved ejection fraction heart failure. Int J Med Sci 2017;14:891–895.
-
(2017)
Int J Med Sci
, vol.14
, pp. 891-895
-
-
Pérez-Belmonte, L.M.1
Moreno-Santos, I.2
Gómez-Doblas, J.J.3
García-Pinilla, J.M.4
Morcillo-Hidalgo, L.5
Garrido-Sánchez, L.6
Santiago-Fernández, C.7
Crespo-Leiro, M.G.8
Carrasco-Chinchilla, F.9
Sánchez-Fernández, P.L.10
de Teresa-Galván, E.11
Jiménez-Navarro, M.12
-
57
-
-
85031691422
-
Characteristics of vessels wall, myocardium and epicardial fat in patients with heart failure with preserved ejection fraction with and without metabolic syndrome
-
Zyatenkova E, Drapkina O, Ivashkin V. Characteristics of vessels wall, myocardium and epicardial fat in patients with heart failure with preserved ejection fraction with and without metabolic syndrome. Endosc Ultrasound 2014;3(Suppl 1):S1–2.
-
(2014)
Endosc Ultrasound
, vol.3
, pp. S1-2
-
-
Zyatenkova, E.1
Drapkina, O.2
Ivashkin, V.3
-
58
-
-
85016580754
-
Biomarker profiles in heart failure patients with preserved and reduced ejection fraction
-
Tromp J, Khan MA, Klip IT, Meyer S, de Boer RA, Jaarsma T, Hillege H, van Veldhuisen DJ, van der Meer P, Voors AA. Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J Am Heart Assoc 2017;6:e003989.
-
(2017)
J Am Heart Assoc
, vol.6
-
-
Tromp, J.1
Khan, M.A.2
Klip, I.T.3
Meyer, S.4
de Boer, R.A.5
Jaarsma, T.6
Hillege, H.7
van Veldhuisen, D.J.8
van der Meer, P.9
Voors, A.A.10
-
59
-
-
85039972259
-
Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction
-
Paulus WJ, Dal Canto E. Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction. JACC Heart Fail 2018;6:1–7.
-
(2018)
JACC Heart Fail
, vol.6
, pp. 1-7
-
-
Paulus, W.J.1
Dal, C.E.2
-
60
-
-
29044444048
-
The effects of atorvastatin (10 mg) on systemic inflammation in heart failure
-
Mozaffarian D, Minami E, Letterer RA, Lawler RL, McDonald GB, Levy WC. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol 2005;96:1699–1704.
-
(2005)
Am J Cardiol
, vol.96
, pp. 1699-1704
-
-
Mozaffarian, D.1
Minami, E.2
Letterer, R.A.3
Lawler, R.L.4
McDonald, G.B.5
Levy, W.C.6
-
61
-
-
38349150595
-
Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy
-
Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51:415–426.
-
(2008)
J Am Coll Cardiol
, vol.51
, pp. 415-426
-
-
Ramasubbu, K.1
Estep, J.2
White, D.L.3
Deswal, A.4
Mann, D.L.5
-
62
-
-
33847309058
-
Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure
-
Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J, Singh B, Tonkin A. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007;13:1–7.
-
(2007)
J Card Fail
, vol.13
, pp. 1-7
-
-
Krum, H.1
Ashton, E.2
Reid, C.3
Kalff, V.4
Rogers, J.5
Amarena, J.6
Singh, B.7
Tonkin, A.8
-
63
-
-
78951482018
-
Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study
-
Ashton E, Windebank E, Skiba M, Reid C, Schneider H, Rosenfeldt F, Tonkin A, Krum H. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol 2011;146:404–407.
-
(2011)
Int J Cardiol
, vol.146
, pp. 404-407
-
-
Ashton, E.1
Windebank, E.2
Skiba, M.3
Reid, C.4
Schneider, H.5
Rosenfeldt, F.6
Tonkin, A.7
Krum, H.8
-
64
-
-
11144355760
-
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
-
Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594–1602.
-
(2004)
Circulation
, vol.109
, pp. 1594-1602
-
-
Mann, D.L.1
McMurray, J.J.2
Packer, M.3
Swedberg, K.4
Borer, J.S.5
Colucci, W.S.6
Djian, J.7
Drexler, H.8
Feldman, A.9
Kober, L.10
Krum, H.11
Liu, P.12
Nieminen, M.13
Tavazzi, L.14
van Veldhuisen, D.J.15
Waldenstrom, A.16
Warren, M.17
Westheim, A.18
Zannad, F.19
Fleming, T.20
more..
-
65
-
-
0038755661
-
Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial
-
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133–3140.
-
(2003)
Circulation
, vol.107
, pp. 3133-3140
-
-
Chung, E.S.1
Packer, M.2
Lo, K.H.3
Fasanmade, A.A.4
Willerson, J.T.5
-
66
-
-
1242315583
-
Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy
-
Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305–311.
-
(2004)
Am J Med
, vol.116
, pp. 305-311
-
-
Wolfe, F.1
Michaud, K.2
-
67
-
-
84891633095
-
Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)
-
Van Tassell BW, Arena R, Biondi-Zoccai G, Canada JM, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, Abbate A. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol 2014;113:321–327.
-
(2014)
Am J Cardiol
, vol.113
, pp. 321-327
-
-
Van Tassell, B.W.1
Arena, R.2
Biondi-Zoccai, G.3
Canada, J.M.4
Oddi, C.5
Abouzaki, N.A.6
Jahangiri, A.7
Falcao, R.A.8
Kontos, M.C.9
Shah, K.B.10
Voelkel, N.F.11
Dinarello, C.A.12
Abbate, A.13
-
68
-
-
84982082404
-
Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial
-
Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP; NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500–508.
-
(2016)
JAMA
, vol.316
, pp. 500-508
-
-
Margulies, K.B.1
Hernandez, A.F.2
Redfield, M.M.3
Givertz, M.M.4
Oliveira, G.H.5
Cole, R.6
Mann, D.L.7
Whellan, D.J.8
Kiernan, M.S.9
Felker, G.M.10
McNulty, S.E.11
Anstrom, K.J.12
Shah, M.R.13
Braunwald, E.14
Cappola, T.P.15
-
69
-
-
84996938099
-
Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) – a multicentre, double-blind, randomised, placebo-controlled trial
-
Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, Nilsson B, Møller JE, Hjort J, Rasmussen J, Boesgaard TW, Schou M, Videbaek L, Gustafsson I, Flyvbjerg A, Wiggers H, Tarnow L. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) – a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19:69–77.
-
(2017)
Eur J Heart Fail
, vol.19
, pp. 69-77
-
-
Jorsal, A.1
Kistorp, C.2
Holmager, P.3
Tougaard, R.S.4
Nielsen, R.5
Hänselmann, A.6
Nilsson, B.7
Møller, J.E.8
Hjort, J.9
Rasmussen, J.10
Boesgaard, T.W.11
Schou, M.12
Videbaek, L.13
Gustafsson, I.14
Flyvbjerg, A.15
Wiggers, H.16
Tarnow, L.17
-
70
-
-
77956618692
-
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
-
Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376:886–894.
-
(2010)
Lancet
, vol.376
, pp. 886-894
-
-
Böhm, M.1
Swedberg, K.2
Komajda, M.3
Borer, J.S.4
Ford, I.5
Dubost-Brama, A.6
Lerebours, G.7
Tavazzi, L.8
-
71
-
-
85032732608
-
Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?
-
627–629.
-
Packer M. Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure? Eur J Heart Fail 2018;20:627–629.
-
(2018)
Eur J Heart Fail
, vol.20
-
-
Packer, M.1
-
72
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128.
-
(2015)
N Engl J Med
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
Fitchett, D.4
Bluhmki, E.5
Hantel, S.6
Mattheus, M.7
Devins, T.8
Johansen, O.E.9
Woerle, H.J.10
Broedl, U.C.11
Inzucchi, S.E.12
-
73
-
-
85034766786
-
Canagliflozin and cardiovascular and renal events in type 2 diabetes
-
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–657.
-
(2017)
N Engl J Med
, vol.377
, pp. 644-657
-
-
Neal, B.1
Perkovic, V.2
Mahaffey, K.W.3
de Zeeuw, D.4
Fulcher, G.5
Erondu, N.6
Shaw, W.7
Law, G.8
Desai, M.9
Matthews, D.R.10
-
74
-
-
84905446525
-
Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models
-
Suzuki M, Takeda M, Kito A, Fukazawa M, Yata T, Yamamoto M, Nagata T, Fukuzawa T, Yamane M, Honda K, Suzuki Y, Kawabe Y. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes 2014;4:e125.
-
(2014)
Nutr Diabetes
, vol.4
-
-
Suzuki, M.1
Takeda, M.2
Kito, A.3
Fukazawa, M.4
Yata, T.5
Yamamoto, M.6
Nagata, T.7
Fukuzawa, T.8
Yamane, M.9
Honda, K.10
Suzuki, Y.11
Kawabe, Y.12
-
75
-
-
85027059141
-
Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study
-
Fukuda T, Bouchi R, Terashima M, Sasahara Y, Asakawa M, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y. Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study. Diabetes Ther 2017;8:851–861.
-
(2017)
Diabetes Ther
, vol.8
, pp. 851-861
-
-
Fukuda, T.1
Bouchi, R.2
Terashima, M.3
Sasahara, Y.4
Asakawa, M.5
Takeuchi, T.6
Nakano, Y.7
Murakami, M.8
Minami, I.9
Izumiyama, H.10
Hashimoto, K.11
Yoshimoto, T.12
Ogawa, Y.13
-
76
-
-
85014337515
-
Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study
-
Bouchi R, Terashima M, Sasahara Y, Asakawa M, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol 2017;16:32.
-
(2017)
Cardiovasc Diabetol
, vol.16
, pp. 32
-
-
Bouchi, R.1
Terashima, M.2
Sasahara, Y.3
Asakawa, M.4
Fukuda, T.5
Takeuchi, T.6
Nakano, Y.7
Murakami, M.8
Minami, I.9
Izumiyama, H.10
Hashimoto, K.11
Yoshimoto, T.12
Ogawa, Y.13
-
77
-
-
85018253813
-
SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor
-
Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther 2017;31:119–132.
-
(2017)
Cardiovasc Drugs Ther
, vol.31
, pp. 119-132
-
-
Ye, Y.1
Bajaj, M.2
Yang, H.C.3
Perez-Polo, J.R.4
Birnbaum, Y.5
-
78
-
-
85010842028
-
Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
-
Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 2017;104:298–310.
-
(2017)
Free Radic Biol Med
, vol.104
, pp. 298-310
-
-
Lee, T.M.1
Chang, N.C.2
Lin, S.Z.3
-
79
-
-
85021069048
-
Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes
-
Hammoudi N, Jeong D, Singh R, Farhat A, Komajda M, Mayoux E, Hajjar R, Lebeche D. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther 2017;31:233–246.
-
(2017)
Cardiovasc Drugs Ther
, vol.31
, pp. 233-246
-
-
Hammoudi, N.1
Jeong, D.2
Singh, R.3
Farhat, A.4
Komajda, M.5
Mayoux, E.6
Hajjar, R.7
Lebeche, D.8
-
80
-
-
85010216514
-
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
-
Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, DeMarco VG. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol 2017;16:9.
-
(2017)
Cardiovasc Diabetol
, vol.16
, pp. 9
-
-
Habibi, J.1
Aroor, A.R.2
Sowers, J.R.3
Jia, G.4
Hayden, M.R.5
Garro, M.6
Barron, B.7
Mayoux, E.8
Rector, R.S.9
Whaley-Connell, A.10
DeMarco, V.G.11
-
81
-
-
85049506770
-
-
Identifier NCT03057951., (2 March 2018)term=empagliflozin&cond=heart+failure&rank=6
-
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved). ClinicalTrials.gov Identifier: NCT03057951. https://clinicaltrials.gov/ct2/show/NCT03057951?term=empagliflozin&cond=heart+failure&rank=6. (2 March 2018)
-
-
-
-
82
-
-
85049527228
-
-
Identifier NCT03057977., (2 March,rank=5
-
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced). ClinicalTrials.gov Identifier: NCT03057977. https://clinicaltrials.gov/ct2/show/NCT03057977?term=empagliflozin&cond=heart+failure&rank=5. (2 March 2018)
-
(2018)
-
-
-
83
-
-
85049537025
-
-
Identifier NCT03036124., (2 March,cond=heart+failure+dapagliflozin&rank=3
-
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (Dapa-HF). ClinicalTrials.gov Identifier: NCT03036124. https://clinicaltrials.gov/ct2/show/NCT03036124?cond=heart+failure+dapagliflozin&rank=3. (2 March 2018)
-
(2018)
-
-
-
84
-
-
85032620814
-
Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action
-
Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2017;2:1025–1029.
-
(2017)
JAMA Cardiol
, vol.2
, pp. 1025-1029
-
-
Packer, M.1
Anker, S.D.2
Butler, J.3
Filippatos, G.4
Zannad, F.5
-
85
-
-
85031915334
-
Activation and inhibition of sodium–hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure
-
Packer M. Activation and inhibition of sodium–hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation 2017;136:1548–1559.
-
(2017)
Circulation
, vol.136
, pp. 1548-1559
-
-
Packer, M.1
-
86
-
-
0037015165
-
Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial
-
Davis BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, Stokes JD; ALLHAT Collaborative Research Group. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Ann Intern Med 2002;137:313–320.
-
(2002)
Ann Intern Med
, vol.137
, pp. 313-320
-
-
Davis, B.R.1
Cutler, J.A.2
Furberg, C.D.3
Wright, J.T.4
Farber, M.A.5
Felicetta, J.V.6
Stokes, J.D.7
-
87
-
-
84963691781
-
Heart failure with preserved ejection fraction in hypertension
-
Teo LY, Chan LL, Lam CS. Heart failure with preserved ejection fraction in hypertension. Curr Opin Cardiol 2016;31:410–416.
-
(2016)
Curr Opin Cardiol
, vol.31
, pp. 410-416
-
-
Teo, L.Y.1
Chan, L.L.2
Lam, C.S.3
-
88
-
-
0022623381
-
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study
-
Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547–1552.
-
(1986)
N Engl J Med
, vol.314
, pp. 1547-1552
-
-
Cohn, J.N.1
Archibald, D.G.2
Ziesche, S.3
Franciosa, J.A.4
Harston, W.E.5
Tristani, F.E.6
Dunkman, W.B.7
Jacobs, W.8
Francis, G.S.9
Flohr, K.H.10
Goldman, S.11
Cobb, F.R.12
Shah, P.M.13
Saunders, R.14
Fletcher, R.D.15
Loeb, H.S.16
Hughes, V.C.17
Baker, B.18
-
89
-
-
84881530438
-
Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2)
-
Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'Connor C, Rouleau JL, Schocken D, Anderson SA, DeMets DL; PRAISE-2 Study Group. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). JACC Heart Fail 2013;1:308–314.
-
(2013)
JACC Heart Fail
, vol.1
, pp. 308-314
-
-
Packer, M.1
Carson, P.2
Elkayam, U.3
Konstam, M.A.4
Moe, G.5
O'Connor, C.6
Rouleau, J.L.7
Schocken, D.8
Anderson, S.A.9
DeMets, D.L.10
-
90
-
-
0346730904
-
Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)
-
Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ; MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003;5:659–667.
-
(2003)
Eur J Heart Fail
, vol.5
, pp. 659-667
-
-
Cohn, J.N.1
Pfeffer, M.A.2
Rouleau, J.3
Sharpe, N.4
Swedberg, K.5
Straub, M.6
Wiltse, C.7
Wright, T.J.8
|